R
4.15
0.31 (8.07%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Relmada Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.3 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 相对估值 | NA |
| 财务健康 | -1.7 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.08 |
|
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 17.00% |
| 机构持股比例 | 33.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Squadron Capital Management Llc | 30 Jun 2026 | 7,350,000 |
| Jones Hill Capital Lp | 30 Jun 2026 | 3,655,075 |
该时间范围内无数据。
该时间范围内无数据。
投资组合